NasdaqGS:CASY
NasdaqGS:CASYConsumer Retailing

Is It Too Late To Consider Casey's After Its 229% Five Year Share Price Surge?

If you are wondering whether Casey's General Stores is still worth considering after such a large run up, or if most of the potential upside is already reflected in the price, this breakdown is designed to help you make sense of what the market is really implying. The stock has climbed 1.4% over the last week, 5.8% over the past month, and 42.7% year to date, with longer term returns of 32.2% over 1 year, 134.1% over 3 years, and 228.3% over 5 years, putting it firmly in market darling...
BIT:NEXI
BIT:NEXIDiversified Financial

How Investors Are Reacting To Nexi (BIT:NEXI) Losing Its Place In Key S&P Global Indices

In late November 2025, Nexi S.p.A. was removed from several major S&P indices, including the S&P Global 1200, S&P International 700, and S&P Europe 350 and its financials sub-indices, reflecting a reclassification of its role in global benchmarks. This broad index exit can change who holds Nexi’s shares, as index-tracking funds adjust their portfolios and active investors reassess its profile. We’ll now examine how Nexi’s broad removal from key S&P indices may influence its investment...
NYSE:ASA
NYSE:ASACapital Markets

Should Saba Capital’s Larger Stake in ASA (ASA) Require Action From Existing Shareholders?

Saba Capital Management, a major shareholder in ASA Gold & Precious Metals, recently expanded its position by purchasing multiple share blocks worth about US$1.64 million, lifting its direct ownership to more than 5.3 million shares. These incremental purchases by an influential investor with over ten percent ownership can shape market perception of ASA Gold & Precious Metals’ prospects and governance direction. We’ll now examine how Saba Capital’s increased ownership stake influences ASA...
TSXV:SNM
TSXV:SNMOil and Gas

TSX Value Picks Estimated To Be Trading Up To 49% Below Intrinsic Value

As we approach the end of 2025, Canadian markets have shown impressive resilience with the TSX posting a robust 27% gain year-to-date, while investors keenly observe potential catalysts such as central bank meetings and labor market reports. In this environment of cautious optimism, identifying undervalued stocks becomes crucial for investors seeking to capitalize on opportunities that may be trading below their intrinsic value.
TSX:CURA
TSX:CURAPharmaceuticals

TSX Growth Stocks With High Insider Ownership To Watch

As we approach the end of 2025, Canadian markets have experienced impressive double-digit gains, with investors closely monitoring central bank decisions and economic indicators for clues on future trends. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, making them worth watching in a climbing market.
NEOE:VRNO
NEOE:VRNOPharmaceuticals

TSX Penny Stock Spotlight: Verano Holdings And Two Other Noteworthy Picks

As we approach the end of 2025, Canadian markets have shown robust performance with significant gains across major indexes, reflecting a cautiously optimistic economic outlook. Amid this backdrop, investors are keenly observing potential shifts in monetary policy from central banks and labor market trends as they strategize for the coming year. While penny stocks might seem like a throwback to earlier market times, they continue to present intriguing opportunities for those seeking growth...
TSXV:HME
TSXV:HMEOil and Gas

3 Dividend Stocks On The TSX With Up To 14.8% Yield

As we approach the end of 2025, Canadian markets have shown impressive resilience, with the TSX up by a robust 27% amid favorable economic conditions and key central bank meetings on the horizon. In this environment, dividend stocks can be an attractive option for investors seeking steady income streams, especially as interest rate decisions and employment data continue to shape market dynamics.
TSE:9434
TSE:9434Wireless Telecom

SoftBank (TSE:9434) Valuation Check as It Joins Nvidia-Led Skild AI Funding Talks

SoftBank (TSE:9434) is back in the AI spotlight, reportedly joining Nvidia in talks to fund Skild AI in a billion dollar plus round that could reshape how investors view SoftBank’s tech exposure. See our latest analysis for SoftBank. All of this comes as SoftBank’s ¥217.3 share price has delivered a solid year to date, with a 10.75% year to date share price return and a 12.63% one year total shareholder return. This builds on a 110.85% five year total shareholder return that signals momentum...
ASX:IMM
ASX:IMMBiotechs

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...
WBAG:VER
WBAG:VERElectric Utilities

How Investors Are Reacting To VERBUND (WBAG:VER) Proposing A €1.15 Per Share Special Dividend

In December 2025, VERBUND AG’s Executive Board proposed to the 2026 Annual General Meeting a special dividend of €1.15 per share for the 2025 financial year, amounting to about €400 million on top of the regular dividend. This additional payout highlights management’s willingness to return a substantial portion of capital to shareholders, potentially influencing perceptions of the company’s cash generation and balance-sheet flexibility. Next, we’ll examine how this proposed €1.15 per share...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex Pharmaceuticals (VRTX): Assessing Valuation After a Strong Multi‑Quarter Run and Recent Pullback

Vertex Pharmaceuticals (VRTX) has quietly outperformed the broader biotech space over the past year, despite a recent pullback. That mix of near term weakness and longer term strength is drawing fresh investor attention. See our latest analysis for Vertex Pharmaceuticals. The latest dip comes after a strong multi quarter run, with a 30 day share price return of 3.75% and a three year total shareholder return of 40.03%. This suggests longer term momentum is still intact even as sentiment cools...
TSE:8001
TSE:8001Trade Distributors

Did ITOCHU's (TSE:8001) E‑Methane Export Push Just Recast Its Low‑Carbon Energy Ambitions?

TotalEnergies, TES, Osaka Gas, Toho Gas, and ITOCHU recently signed a Joint Development and Operating Agreement for the Live Oak e-methane project in Nebraska, targeting around 250 MW of electrolysis and 75 ktpa of methanation with commercial operations planned by 2030. By coordinating Japanese participation in this carbon-neutral gas initiative, ITOCHU is helping unlock e-methane exports to Japan using existing LNG infrastructure and biogenic CO2 resources. We’ll now examine how ITOCHU’s...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

Extreme Networks (EXTR): Valuation Check as Platform ONE Pivot Boosts Recurring and Deferred Revenue

Extreme Networks (EXTR) is getting fresh attention as investors digest its pivot from legacy hardware sales to a Platform ONE centered subscription model, reshaping how the company earns, smooths, and forecasts revenue. See our latest analysis for Extreme Networks. The latest pivot news lands after a choppy stretch, with the share price at $18.06 and a roughly 21% 3 month share price decline. This contrasts with a still impressive 5 year total shareholder return above 170%, suggesting longer...
NYSE:FTI
NYSE:FTIEnergy Services

Assessing TechnipFMC (NYSE:FTI) Valuation After a Strong Multi‑Year Share Price Run

TechnipFMC (FTI) has quietly built an impressive track record, with the stock up about 55% this year and roughly 3 times over the past 3 years, driven by steady revenue and earnings growth. See our latest analysis for TechnipFMC. The recent 1 month share price return of 4.85% and 3 month share price return of 13.8% suggest momentum is still building. At the same time, the 3 year total shareholder return above 300% highlights how consistently the story has been rewarded over time. If...
NasdaqGS:AVAH
NasdaqGS:AVAHHealthcare

Assessing Aveanna Healthcare (AVAH) Valuation After Bullish Analyst Coverage and Strong Quarterly Results

William Blair’s upbeat coverage initiation on Aveanna Healthcare Holdings (AVAH), coming on the heels of strong quarterly results and favorable regulatory trends, has sharpened investor attention just as management heads into the Bank of America Home Care Conference. See our latest analysis for Aveanna Healthcare Holdings. Those strong quarterly numbers and upbeat coverage have come after a powerful run, with the share price up more than 100% year to date and the three year total shareholder...